+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
PDGFR Inhibitor Market by Indication, Drug Type, Delivery Route, End User, Sales Channel - Global Forecast to 2030- Product Image
PDGFR Inhibitor Market by Indication, Drug Type, Delivery Route, End User, Sales Channel - Global Forecast to 2030- Product Image
Sale

PDGFR Inhibitor Market by Indication, Drug Type, Delivery Route, End User, Sales Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 184 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6016422
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The PDGFR Inhibitor Market grew from USD 3.43 billion in 2024 to USD 3.60 billion in 2025. It is expected to continue growing at a CAGR of 4.99%, reaching USD 4.59 billion by 2030.

Setting the Stage for Precision in PDGFR-Targeted Therapy

The inhibition of platelet-derived growth factor receptors has emerged as a cornerstone strategy in combating malignancies driven by aberrant signalling pathways. With advances in molecular biology and drug discovery platforms, novel PDGFR inhibitors have shown remarkable potential across indications that were previously difficult to manage. This executive summary opens by contextualizing the evolution of targeted therapies, highlighting the shift from broad-spectrum chemotherapeutics to precision medicines that selectively disrupt pathological signalling cascades.

In recent years, the convergence of genomics, proteomics and high-throughput screening has accelerated the identification of candidate molecules capable of binding PDGFR isoforms with high affinity. This has translated into clinical breakthroughs, particularly in diseases characterized by dysregulated PDGF signalling. As you delve further, you will gain an in-depth understanding of the scientific rationale, key stakeholder perspectives and emerging trends shaping this dynamic space.

Milestones and Innovations Redefining PDGFR Inhibitor Development

The PDGFR inhibitor landscape has undergone transformative shifts driven by technological innovation and evolving clinical paradigms. Next-generation small molecule inhibitors have leveraged structure-based design to achieve subnanomolar potency and enhanced selectivity, mitigating off-target effects that once limited clinical utility. At the same time, advances in monoclonal antibody engineering have yielded fully human constructs that minimize immunogenicity while retaining robust receptor blockade.

Parallel to molecular refinement, real-world evidence has informed streamlined trial designs and adaptive endpoints, fostering faster pathways to approval. Adaptive licensing frameworks in key markets have granted earlier patient access without compromising safety standards. Moreover, the integration of companion diagnostics has ensured that only patients with PDGFR-driven pathophysiology receive these specialized interventions, optimizing therapeutic outcomes. Together, these developments signal a new era of precision medicine where PDGFR inhibitors occupy a central role.

Assessing the 2025 U.S. Tariff Impact on PDGFR Inhibitor Supply Chains

In 2025, the U.S. government implemented a series of tariffs affecting active pharmaceutical ingredients and key manufacturing equipment imported from strategic regions. While the stated objective was to bolster domestic production, the immediate repercussion for PDGFR inhibitor development was a notable rise in input costs. Contract research organizations and small to mid-size biotechs encountered increased overhead for murine models, cell culture reagents and specialized laboratory instrumentation.

In response, many companies relocated portions of their synthetic chemistry and formulation work back to U.S. facilities, embracing vertical integration as a hedge against future trade uncertainties. This shift has driven consolidation among service providers, with a handful of large CDMOs capturing a greater share of outsourced development projects. Ultimately, although near-term cost pressures intensified, the tariffs have catalysed a strategic realignment that may enhance supply chain resilience and expedite domestic manufacturing capacity.

Dissecting Market Segmentation to Uncover Strategic Levers

A nuanced understanding of market segmentation is critical for identifying growth opportunities and addressing unmet needs. When dissected by indication, the landscape is dominated by treatments for chronic myeloid leukemia alongside gastrointestinal stromal tumors, reflecting the highest incidence and strongest clinical validation. This bifurcation has guided investment priorities and clinical trial pipelines, ensuring that resources align with disease burden.

Analyzing the market through the lens of drug type reveals two principal categories: monoclonal antibodies and small molecule inhibitors. Within the monoclonal antibody segment, fully human antibodies have emerged as the gold standard, thanks to low immunogenic profiles and extended half-lives, while humanized constructs continue to play a complementary role in bridging innovation. Meanwhile, the small molecule inhibitor category spans three generations: first-generation compounds established proof of concept but faced selectivity challenges, second-generation molecules improved potency and safety margins, and the most recent third-generation inhibitors have achieved exquisite target specificity and favourable pharmacokinetic profiles.

Delivery route further stratifies the landscape. Intravenous administration, subdivided into infusion and injection modalities, remains prevalent in hospital settings and specialty clinics due to its rapid bioavailability and controlled dosing. Oral therapies, available in capsule and tablet forms, have gained traction for their convenience and patient adherence benefits, particularly in ambulatory environments. This dichotomy has fuelled formulation innovations aimed at balancing pharmacodynamic requirements with patient-centric design.

End user insights underscore the importance of channel-specific dynamics. Ambulatory surgical centers and hospitals drive high-volume intravenous utilization, whereas specialty clinics often spearhead early adoption of novel oral regimens. Sales channels, comprising hospital pharmacies, online pharmacies and retail pharmacies, each exhibit unique procurement cycles and reimbursement frameworks. Understanding how these channels intersect with prescribing practices is vital for optimizing market access strategies and ensuring seamless product availability.

Regional Dynamics Driving PDGFR Inhibitor Uptake Worldwide

Regional dynamics play a pivotal role in shaping PDGFR inhibitor adoption. In the Americas, robust healthcare infrastructure and a strong emphasis on innovation have accelerated the uptake of both novel and follow-on compounds. Payers in this region are increasingly leveraging health economics and outcomes research to guide formulary decisions, pushing manufacturers to demonstrate real-world value beyond clinical trial data.

Across Europe, the Middle East and Africa, diverse regulatory frameworks present both challenges and opportunities. While major European markets offer expedited review pathways and well-established reimbursement processes, emerging economies in the Middle East and Africa require tailored market entry strategies that account for variable healthcare spending and local manufacturing imperatives. Collaborative partnerships with regional distributors and technology transfer agreements have become essential in these heterogeneous markets.

The Asia-Pacific landscape stands out for its rapid growth trajectory and large patient populations. Countries such as Japan and South Korea have advanced regulatory systems that support early access programs. Meanwhile, markets like China and India combine vast patient pools with evolving biosimilar ecosystems, compelling multinational players to adopt flexible pricing models and localized production to remain competitive.

Examining Competitive Strategies and Collaborative Breakthroughs

Leading companies have distinguished themselves through differentiated pipelines and strategic collaborations. Global pharmas have secured late-stage assets via in-licensing deals, while biotech innovators are pushing the envelope with bispecific antibodies and antibody-drug conjugates targeting PDGFR. Key players are integrating artificial intelligence into their discovery platforms, shortening lead optimization timelines and identifying novel binding pockets.

Strategic partnerships between academic institutions and industry are proliferating, yielding translational research hubs that fast-track preclinical candidates into clinical evaluation. Concurrently, contract development and manufacturing organizations have expanded their service offerings to include integrated process development and regulatory support, enabling smaller sponsors to navigate complex approval pathways.

Competitive differentiation also stems from lifecycle management strategies. Several companies are investing in formulation enhancements, such as sustained-release oral capsules, to extend patent exclusivity and improve patient adherence. Others are exploring combination regimens that pair PDGFR inhibitors with immunotherapies or targeted agents, aiming to overcome resistance mechanisms and expand therapeutic indications.

Strategic Imperatives for Maximizing Market Potential

To capitalize on the evolving PDGFR inhibitor landscape, industry leaders should prioritize several strategic imperatives. First, establishing integrated discovery platforms that converge computational modelling with high-throughput screening can accelerate target validation and reduce lead times. Second, forging early alliances with regional partners will be essential for navigating diverse regulatory requirements and optimizing local manufacturing footprints.

Furthermore, companies must craft differentiated market access strategies that emphasize real-world evidence and health economic data, ensuring payers recognize the long-term value of innovative therapies. Investing in patient support programs and digital health tools will bolster adherence and reinforce brand loyalty. In parallel, exploring combination therapies with complementary mechanisms of action can address resistance pathways and unlock new indications, thereby extending the commercial lifespan of core assets.

Finally, operational resilience should remain a focus. Diversifying supply chains and cultivating flexible manufacturing capacity will mitigate the impact of future trade disruptions. By aligning R&D priorities with a clear understanding of payer and patient needs, organizations can seize growth opportunities and maintain competitive advantage.

Methodological Framework Underpinning Our Insights

This analysis draws upon a multi-faceted research methodology designed to ensure comprehensive, unbiased insights. Primary interviews with key opinion leaders, including oncologists, pharmacologists and payers, provided qualitative context on clinical adoption and reimbursement trends. These discussions were complemented by in-depth conversations with senior executives at leading biopharmaceutical companies and contract research organizations.

Secondary research encompassed peer-reviewed journals, regulatory filings, company financial reports and patent databases. This rigorous triangulation of data sources allowed for cross-validation of emerging hypotheses. Additionally, proprietary databases tracking clinical trial activity and drug approvals were leveraged to map the competitive landscape and identify white space opportunities.

Quantitative analysis incorporated historical trial outcomes and real-world utilization metrics to inform risk assessments and strategic recommendations. Geographic and segment-specific insights were enriched through scenario modelling, capturing the impact of policy shifts, tariff changes and evolving reimbursement frameworks. The result is a robust, 360-degree perspective on the PDGFR inhibitor ecosystem.

Closing Reflections on Future Growth and Innovation

The PDGFR inhibitor arena stands at a pivotal inflection point, poised for continued innovation and accelerated adoption. As scientific advances converge with pragmatic access considerations, stakeholders who embrace precision development, strategic collaborations and resilient operations will shape the next generation of targeted therapies. This executive summary has illuminated the critical trends, segmentation nuances and regional dynamics that will define success in this competitive landscape.

Moving forward, the integration of real-world evidence, adaptive development strategies and patient-centric approaches will be key differentiators. By aligning R&D investments with evolving payer expectations and leveraging strategic partnerships, organizations can navigate complexity and deliver transformative outcomes for patients.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Indication
    • Chronic Myeloid Leukemia
    • Gastrointestinal Stromal Tumors
  • Drug Type
    • Monoclonal Antibody
      • Fully Human
      • Humanized
    • Small Molecule Inhibitor
      • First Generation
      • Second Generation
      • Third Generation
  • Delivery Route
    • Intravenous
      • Infusion
      • Injection
    • Oral
      • Capsule
      • Tablet
  • End User
    • Ambulatory Surgical Centers
    • Hospitals
    • Specialty Clinics
  • Sales Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Novartis AG
  • Pfizer Inc.
  • Bayer AG
  • Ipsen S.A.
  • Exelixis, Inc.
  • Bristol-Myers Squibb Company
  • AstraZeneca PLC
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Boehringer Ingelheim International GmbH

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. PDGFR Inhibitor Market, by Indication
8.1. Introduction
8.2. Chronic Myeloid Leukemia
8.3. Gastrointestinal Stromal Tumors
9. PDGFR Inhibitor Market, by Drug Type
9.1. Introduction
9.2. Monoclonal Antibody
9.2.1. Fully Human
9.2.2. Humanized
9.3. Small Molecule Inhibitor
9.3.1. First Generation
9.3.2. Second Generation
9.3.3. Third Generation
10. PDGFR Inhibitor Market, by Delivery Route
10.1. Introduction
10.2. Intravenous
10.2.1. Infusion
10.2.2. Injection
10.3. Oral
10.3.1. Capsule
10.3.2. Tablet
11. PDGFR Inhibitor Market, by End User
11.1. Introduction
11.2. Ambulatory Surgical Centers
11.3. Hospitals
11.4. Specialty Clinics
12. PDGFR Inhibitor Market, by Sales Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Online Pharmacies
12.4. Retail Pharmacies
13. Americas PDGFR Inhibitor Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa PDGFR Inhibitor Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific PDGFR Inhibitor Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Novartis AG
16.3.2. Pfizer Inc.
16.3.3. Bayer AG
16.3.4. Ipsen S.A.
16.3.5. Exelixis, Inc.
16.3.6. Bristol-Myers Squibb Company
16.3.7. AstraZeneca PLC
16.3.8. Eli Lilly and Company
16.3.9. Merck & Co., Inc.
16.3.10. Boehringer Ingelheim International GmbH
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. PDGFR INHIBITOR MARKET MULTI-CURRENCY
FIGURE 2. PDGFR INHIBITOR MARKET MULTI-LANGUAGE
FIGURE 3. PDGFR INHIBITOR MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL PDGFR INHIBITOR MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. PDGFR INHIBITOR MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. PDGFR INHIBITOR MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. PDGFR INHIBITOR MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PDGFR INHIBITOR MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY FULLY HUMAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY INFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 56. CANADA PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 57. CANADA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 58. CANADA PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 59. CANADA PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 60. CANADA PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 61. CANADA PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 62. CANADA PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 63. CANADA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. CANADA PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. MEXICO PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 66. MEXICO PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 67. MEXICO PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 68. MEXICO PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 69. MEXICO PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 70. MEXICO PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 71. MEXICO PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 72. MEXICO PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 73. MEXICO PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 102. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 103. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 104. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 105. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 106. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 107. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 108. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 109. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 110. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 111. GERMANY PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 112. GERMANY PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 113. GERMANY PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 114. GERMANY PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 115. GERMANY PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 116. GERMANY PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 117. GERMANY PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 118. GERMANY PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. GERMANY PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. FRANCE PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 121. FRANCE PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 122. FRANCE PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 123. FRANCE PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 124. FRANCE PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 125. FRANCE PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 126. FRANCE PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 127. FRANCE PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. FRANCE PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 129. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 130. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 131. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 132. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 133. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 134. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 135. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 136. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. ITALY PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 139. ITALY PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 140. ITALY PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 141. ITALY PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 142. ITALY PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 143. ITALY PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 144. ITALY PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 145. ITALY PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. ITALY PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 147. SPAIN PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 148. SPAIN PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 149. SPAIN PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 150. SPAIN PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 151. SPAIN PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 152. SPAIN PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 153. SPAIN PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 154. SPAIN PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 155. SPAIN PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 156. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 157. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 158. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 159. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 160. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 161. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 162. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 163. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 164. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 166. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 167. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 168. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 169. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 170. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 171. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 172. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. SOUTH AFRICA PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 175. SOUTH AFRICA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 176. SOUTH AFRICA PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 177. SOUTH AFRICA PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 178. SOUTH AFRICA PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 179. SOUTH AFRICA PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 180. SOUTH AFRICA PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 181. SOUTH AFRICA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 182. SOUTH AFRICA PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 183. DENMARK PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 184. DENMARK PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 185. DENMARK PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 186. DENMARK PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 187. DENMARK PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 188. DENMARK PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 189. DENMARK PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 190. DENMARK PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. DENMARK PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. NETHERLANDS PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 193. NETHERLANDS PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 194. NETHERLANDS PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 195. NETHERLANDS PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 196. NETHERLANDS PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 197. NETHERLANDS PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 198. NETHERLANDS PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 199. NETHERLANDS PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 201. QATAR PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 202. QATAR PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 203. QATAR PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 204. QATAR PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 205. QATAR PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 206. QATAR PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 207. QATAR PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 208. QATAR PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. QATAR PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 210. FINLAND PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 211. FINLAND PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 212. FINLAND PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 213. FINLAND PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 214. FINLAND PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 215. FINLAND PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 216. FINLAND PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 217. FINLAND PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. FINLAND PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 219. SWEDEN PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 220. SWEDEN PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 221. SWEDEN PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 222. SWEDEN PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 223. SWEDEN PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 224. SWEDEN PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 225. SWEDEN PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 226. SWEDEN PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 227. SWEDEN PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 228. NIGERIA PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 229. NIGERIA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 230. NIGERIA PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 231. NIGERIA PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 232. NIGERIA PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 233. NIGERIA PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 234. NIGERIA PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 235. NIGERIA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 236. NIGERIA PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 237. EGYPT PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 238. EGYPT PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 239. EGYPT PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 240. EGYPT PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 241. EGYPT PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 242. EGYPT PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 243. EGYPT PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 244. EGYPT PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 245. EGYPT PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 246. TURKEY PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 247. TURKEY PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 248. TURKEY PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 249. TURKEY PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 250. TURKEY PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 251. TURKEY PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 252. TURKEY PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 253. TURKEY PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 254. TURKEY PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 255. ISRAEL PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 256. ISRAEL PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 257. ISRAEL PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 258. ISRAEL PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 259. ISRAEL PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 260. ISRAEL PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 261. ISRAEL PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 262. ISRAEL PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 263. ISRAEL PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 264. NORWAY PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 265. NORWAY PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 266. NORWAY PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 267. NORWAY PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 268. NORWAY PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 269. NORWAY PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 270. NORWAY PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 271. NORWAY PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 272. NORWAY PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 273. POLAND PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 274. POLAND PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 275. POLAND PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 276. POLAND PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 277. POLAND PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 278. POLAND PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 279. POLAND PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 280. POLAND PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 281. POLAND PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 282. SWITZERLAND PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 283. SWITZERLAND PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 284. SWITZERLAND PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 285. SWITZERLAND PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 286. SWITZERLAND PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 287. SWITZERLAND PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 288. SWITZERLAND PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 289. SWITZERLAND PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 290. SWITZERLAND PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 291. ASIA-PACIFIC PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 292. ASIA-PACIFIC PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 293. ASIA-PACIFIC PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 294. ASIA-PACIFIC PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 295. ASIA-PACIFIC PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 296. ASIA-PACIFIC PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 297. ASIA-PACIFIC PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 298. ASIA-PACIFIC PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 299. ASIA-PACIFIC PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 300. ASIA-PACIFIC PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 301. CHINA PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 302. CHINA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 303. CHINA PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 304. CHINA PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 305. CHINA PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 306. CHINA PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 307. CHINA PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 308. CHINA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 309. CHINA PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 310. INDIA PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 311. INDIA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 312. INDIA PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 313. INDIA PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 314. INDIA PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 315. INDIA PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 316. INDIA PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 317. INDIA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 318. INDIA PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 319. JAPAN PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 320. JAPAN PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 321. JAPAN PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 322. JAPAN PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 323. JAPAN PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 324. JAPAN PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 325. JAPAN PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 326. JAPAN PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 327. JAPAN PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 328. AUSTRALIA PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 329. AUSTRALIA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 330. AUSTRALIA PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 331. AUSTRALIA PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 332. AUSTRALIA PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 333. AUSTRALIA PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 334. AUSTRALIA PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 335. AUSTRALIA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 336. AUSTRALIA PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 337. SOUTH KOREA PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 338. SOUTH KOREA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 339. SOUTH KOREA PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 340. SOUTH KOREA PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 341. SOUTH KOREA PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 342. SOUTH KOREA PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 343. SOUTH KOREA PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 344. SOUTH KOREA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 345. SOUTH KOREA PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 346. INDONESIA PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 347. INDONESIA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 348. INDONESIA PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 349. INDONESIA PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 350. INDONESIA PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 351. INDONESIA PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 352. INDONESIA PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 353. INDONESIA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 354. INDONESIA PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 355. THAILAND PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 356. THAILAND PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 357. THAILAND PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 358. THAILAND PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 359. THAILAND PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 360. THAILAND PDGFR INHIBITOR MARKET SIZE, BY INTRAVEN

Companies Mentioned

The companies profiled in this PDGFR Inhibitor market report include:
  • Novartis AG
  • Pfizer Inc.
  • Bayer AG
  • Ipsen S.A.
  • Exelixis, Inc.
  • Bristol-Myers Squibb Company
  • AstraZeneca PLC
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Boehringer Ingelheim International GmbH

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages184
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 3.6 Billion
Forecasted Market Value ( USD ) by 2030 $ 4.59 Billion
Compound Annual Growth Rate4.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

RANKL Inhibitors Market by Product Type, Route of Administration, Application, End-User, Distribution Channel - Global Forecast to 2030 - Product Image

RANKL Inhibitors Market by Product Type, Route of Administration, Application, End-User, Distribution Channel - Global Forecast to 2030

  • Report
  • 193 Pages
  • Global
From
Pruritus Therapeutics Market by Therapy, Route of Administration, Disease Indication, Patient Demographics, Distribution Channel, End-User - Global Forecast to 2030 - Product Image

Pruritus Therapeutics Market by Therapy, Route of Administration, Disease Indication, Patient Demographics, Distribution Channel, End-User - Global Forecast to 2030

  • Report
  • 186 Pages
  • Global
From
Feiba VH Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Feiba VH Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 175 Pages
  • Global
From
Feiba NF Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Feiba NF Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 175 Pages
  • Global
From
RAGE Inhibitor - Pipeline Insight, 2025 - Product Image

RAGE Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.